User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Apixaban with antiplatelet therapy after acute coronary syndrome.

Primary tabs

Alexander, John H Lopes, Renato D James, Stefan Kilaru, Rakhi He, Yaohua Dangoisse, Vincent [UCL]

The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2011
Language Anglais
Journal information "New England Journal of Medicine" - Vol. 365, no.8, p. 699-708 (2011)
Peer reviewed yes
Publisher Massachusetts Medical Society ((United States) [S.l.])
issn 0028-4793
e-issn 1533-4406
Publication status Publié
Affiliation UCL - (MGD) Service de cardiologie
MESH Subject Acute Coronary Syndrome ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myocardial Infarction ; Platelet Aggregation Inhibitors ; Proportional Hazards Models ; Pyrazoles ; Pyridones ; Stroke ; Aged ; Treatment Outcome ; Angina, Unstable ; Aspirin ; Double-Blind Method ; Drug Therapy, Combination ; Factor Xa ; Female ; Hemorrhage
Links
Bibliographic reference Alexander, John H ; Lopes, Renato D ; James, Stefan ; Kilaru, Rakhi ; He, Yaohua ; et. al. Apixaban with antiplatelet therapy after acute coronary syndrome.. In: New England Journal of Medicine, Vol. 365, no.8, p. 699-708 (2011)
Permanent URL http://hdl.handle.net/2078.1/126571